SG Americas Securities’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.49M Sell
307,721
-4,433
-1% -$42.8K ﹤0.01% 1141
2026
Q1
$2.32M Sell
312,154
-2,217
-0.7% -$23.3K ﹤0.01% 1322
2025
Q4
$3.7M Buy
314,371
+260,101
+479% +$2.81M ﹤0.01% 1224
2025
Q3
$419K Sell
54,270
-118,068
-69% -$827K ﹤0.01% 2246
2025
Q2
$1.26M Buy
+172,338
New +$1.39M 0.01% 1015
2024
Q4
Sell
-21,136
Closed -$312K 3445
2024
Q3
$312K Buy
+21,136
New +$331K ﹤0.01% 2115
2024
Q2
Sell
-63,980
Closed -$1.01M 3150
2024
Q1
$1.01M Sell
63,980
-21,766
-25% -$336K ﹤0.01% 1133
2023
Q4
$1.39M Sell
85,746
-64,199
-43% -$1.05M 0.01% 856
2023
Q3
$1.84M Buy
+149,945
New +$2.23M 0.02% 791
2023
Q2
Sell
-197,828
Closed -$3.44M 2867
2023
Q1
$3.44M Buy
197,828
+168,095
+565% +$2.39M 0.04% 406
2022
Q4
$275K Sell
29,733
-151,048
-84% -$1.41M ﹤0.01% 1991
2022
Q3
$1.56M Sell
180,781
-62,272
-26% -$618K 0.02% 725
2022
Q2
$1.98M Buy
243,053
+82,681
+52% +$789K 0.02% 755
2022
Q1
$1.95M Sell
160,372
-105,879
-40% -$2.23M 0.01% 935
2021
Q4
$9.08M Buy
266,251
+52,181
+24% +$2.04M 0.05% 294
2021
Q3
$10.3M Buy
214,070
+32,652
+18% +$1.51M 0.05% 254
2021
Q2
$8.2M Buy
181,418
+152,504
+527% +$6.76M 0.04% 420
2021
Q1
$1.4M Sell
28,914
-15,593
-35% -$812K 0.01% 1301
2020
Q4
$2.4M Buy
44,507
+29,697
+201% +$1.34M 0.01% 981
2020
Q3
$546K Buy
14,810
+6,605
+80% +$246K ﹤0.01% 1574
2020
Q2
$254K Sell
8,205
-12,243
-60% -$339K ﹤0.01% 2653
2020
Q1
$565K Buy
20,448
+8,470
+71% +$254K 0.01% 1751
2019
Q4
$350K Sell
11,978
-30,106
-72% -$717K ﹤0.01% 2068
2019
Q3
$805K Buy
42,084
+25,421
+153% +$596K 0.01% 1554
2019
Q2
$366K Buy
16,663
+11,537
+225% +$253K ﹤0.01% 2082
2019
Q1
$105K Sell
5,126
-108,851
-96% -$1.89M ﹤0.01% 3039
2018
Q4
$1.44M Buy
+113,977
New +$1.7M 0.01% 1090

Other funds holding NEO

SG Americas Securities's NEO Position: Q2 2026 in Review

SG Americas Securities reduced its NeoGenomics (NEO) stake by 1.4% in Q2 2026, selling an estimated $42.8K and leaving 307,721 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

SG Americas Securities first reported a position in NEO in Q4 2018 and has held it in 27 quarters since. The position peaked at $10.3M in Q3 2021. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • SG Americas Securities held 307,721 shares of NeoGenomics worth $4.49M as of Q2 2026.
  • SG Americas Securities sold 4,433 NeoGenomics shares in Q2 2026, an estimated $42.8K.
  • NeoGenomics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1141 holding.
  • SG Americas Securities first reported a position in NeoGenomics in Q4 2018 and has held it in 27 quarters since.
  • SG Americas Securities's NeoGenomics position peaked at $10.3M in Q3 2021.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.